HEALWELL AI’s Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema

TORONTO, June 06, 2024 (GLOBE NEWSWIRE) — HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX:AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is proud to announce its subsidiary Pentavere Research Group (“Pentavere”) have engaged in a partnership and commercial engagement with Takeda Canada Inc. (“Takeda”) to drive real-world evidence analysis for rare diseases, particularly focusing on supporting patients suffering from hereditary angioedema (HAE) with normal C1 inhibitor across Canada. HAE with normal C1 inhibitor is an ultra-rare disease characterized by life-threatening recurrent, unpredictable swelling, and currently does not have any approved treatments.

Read more at globenewswire.com